Lexicon Pharmaceuticals has made progress in getting its lead drug Inpefa onto formularies and securing reimbursement agreements with insurers. Multiple studies support the cost efficacy of Inpefa for ...
Lexicon Pharmaceuticals is actively working to create shareholder value by pursuing new indications for the lead drug sotagliflozin. The company reported $0.7 million in Inpefa sales for Q4 2023, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results